Tumor Mutational Burden and Other Predictive Immunotherapy Markers in Histiocytic Neoplasms

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2019 Jan 31

PMID 30696619

Citations 14

Authors

Gaurav Goyal

Denise Lau

Alison M Nagle

Robert Vassallo

Karen L Rech

Jay H Ryu

Caroline J Davidge-Pitts

W Oliver Tobin

Matthew J Koster

N Nora Bennani

Mithun V Shah

Minetta C Liu

Ronald S Go

Affiliations

Soon will be listed here.

Citing Articles

Retrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes.

Asano T, Morimoto A, Nakazawa A, Ueda T, Ogawa C, Sakata N Int J Hematol. 2025; .

PMID: 40063331 DOI: 10.1007/s12185-025-03962-w.

Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma.

Lenz J, Peng B, Assenmacher C, King A, Zhang P, Maki R Cancer Immunol Immunother. 2025; 74(2):61.

PMID: 39751954 PMC: 11699166. DOI: 10.1007/s00262-024-03908-x.

Rosai-Dorfman-Destombes disease in adults: a single center experience.

Leung E, Pryma C, Murphy S, Harrison R, Peterson E, Tsang P Ann Hematol. 2024; 103(11):4467-4476.

PMID: 39331156 DOI: 10.1007/s00277-024-06019-w.

Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report.

Nguyen L, Pham G, Vu P, Yi H Ann Med Surg (Lond). 2023; 85(12):6274-6278.

PMID: 38098600 PMC: 10718375. DOI: 10.1097/MS9.0000000000001446.

Multi-omic analysis in normal colon organoids highlights MSH4 as a novel marker of defective mismatch repair in Lynch syndrome and microsatellite instability.

Devall M, Ali M, Eaton S, Weisenberger D, Reilley M, Powell S Cancer Med. 2023; 12(12):13551-13572.

PMID: 37162286 PMC: 10315803. DOI: 10.1002/cam4.6048.

References

Garces S, Medeiros L, Patel K, Li S, Pina-Oviedo S, Li J . Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017; 30(10):1367-1377. PMC: 5837474. DOI: 10.1038/modpathol.2017.55. View

Gatalica Z, Bilalovic N, Palazzo J, Bender R, Swensen J, Millis S . Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget. 2015; 6(23):19819-25. PMC: 4637323. DOI: 10.18632/oncotarget.4378. View

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

Bose S, Robles J, McCall C, Lagoo A, Wechsler D, Schooler G . Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma. Pediatr Blood Cancer. 2018; 66(1):e27491. PMC: 6433376. DOI: 10.1002/pbc.27491. View

Goyal G, Shah M, Hook C, Wolanskyj A, Call T, Rech K . Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. Br J Haematol. 2017; 182(4):579-581. DOI: 10.1111/bjh.14818. View

Patel S, Kurzrock R . PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14(4):847-56. DOI: 10.1158/1535-7163.MCT-14-0983. View

Cohen-Aubart F, Emile J, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F . Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. Am J Hematol. 2018; 93(5):E114-E117. DOI: 10.1002/ajh.25055. View

Diamond E, Subbiah V, Lockhart A, Blay J, Puzanov I, Chau I . Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol. 2017; 4(3):384-388. PMC: 5844839. DOI: 10.1001/jamaoncol.2017.5029. View

Yarchoan M, Hopkins A, Jaffee E . Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25):2500-2501. PMC: 6549688. DOI: 10.1056/NEJMc1713444. View

10.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

11.

Goodman A, Kato S, Bazhenova L, Patel S, Frampton G, Miller V . Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017; 16(11):2598-2608. PMC: 5670009. DOI: 10.1158/1535-7163.MCT-17-0386. View

12.

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View

13.

Beaubier N, Tell R, Huether R, Bontrager M, Bush S, Parsons J . Clinical validation of the Tempus xO assay. Oncotarget. 2018; 9(40):25826-25832. PMC: 5995233. DOI: 10.18632/oncotarget.25381. View

14.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

15.

Diamond E, Durham B, Haroche J, Yao Z, Ma J, Parikh S . Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov. 2015; 6(2):154-65. PMC: 4744547. DOI: 10.1158/2159-8290.CD-15-0913. View

16.

Kommalapati A, Tella S, Durkin M, Go R, Goyal G . Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 2017; 131(2):265-268. PMC: 5757688. DOI: 10.1182/blood-2017-10-812495. View

17.

Goyal G, Shah M, Call T, Litzow M, Hogan W, Go R . Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. JAMA Oncol. 2017; 3(9):1253-1256. PMC: 5824289. DOI: 10.1001/jamaoncol.2017.0041. View

18.

Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409-413. PMC: 5576142. DOI: 10.1126/science.aan6733. View

19.

Badalian-Very G, Vergilio J, Degar B, Macconaill L, Brandner B, Calicchio M . Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010; 116(11):1919-23. PMC: 3173987. DOI: 10.1182/blood-2010-04-279083. View